As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a ...

Eli Lilly said its phase 3 trial of GLP-1 drug in pill form found results similar to popular injectables for weight loss. Orforglipron would be used as a daily pill, eliminating the need for ...

The positive data gives Eli Lilly the green light to file the drug with the FDA by the end of the year for a weight-loss indication.

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.